



Dr. Reddy's Gets DCGI Nod For Single-Shot Sputnik Light Vaccine In India

Monal Sanghvi

Posted On 11:16 AM IST, 07 Feb 2022

Updated On 11:16 AM IST, 07 Feb 2022

Posted On 11:16 AM IST, 07 Feb 2022

Updated On 11:16 AM IST, 07 Feb 2022

Save

Dr. Reddy's Laboratories Ltd. has received India's drug regulator's approval for a single-shot Covid-19 vaccine as part of the nation's inoculation effort in the fight against the pandemic.

The Drugs Controller General of India has granted approval to the single-shot Sputnik Light vaccine for restricted use in emergency situation in India, the Hyderabad-based pharmaceutical company said in an exchange filing. That's the ninth vaccine to be approved for emergency use in the country, and the second by Dr. Reddy's.

In September 2020, Dr. Reddy's partnered the Russian Direct Investment Fund to conduct clinical trials of Sputnik V and distribute the vaccine in India. In April 2021, the DCGI granted approval to the two-dose Sputnik V vaccine for restricted use in emergency situation. In December, after the phase-III clinical trial (safety and efficacy) of the single-shot vaccine in India, Dr. Reddy's submitted its application for approval to the regulator.

Sputnik Light has been approved in more than 30 countries, including Argentina, the U.A.E., the Philippines and Russia, the filing said.

Shares of Dr. Reddy's opened around 5.7% higher after the announcement but pared all gains to trade 1.3% lower as of 11 a.m., compared with the Sensex's 0.6% decline.

Stay Updated With **Business News** On BloombergQuint

GET REGULAR UPDATES



BloombergQuint
Join WhatsApp Channel >



BloombergQuint
Join Telegram Channel >



BloombergQuint
Get Daily Newsletters >



BloombergQuint
Subscribe to Notifications >